| Autor: |
Auber ML; Department of Medicine, West Virginia University Medical Center, Morgantown., DeHaven JI, Raich PC, Rogers JS 2nd, Crowell EB Jr, Romero P, Mahin EJ, Sosnowski JT, Lamm DL |
| Jazyk: |
angličtina |
| Zdroj: |
The West Virginia medical journal [W V Med J] 1991 Aug; Vol. 87 (8), pp. 344-6. |
| Abstrakt: |
Interleukin-2 (IL-2) is a substance produced by activated blood cells called helper T-lymphocytes and has been shown to stimulate the body's immune system. IL-2 may cause certain tumors to regress when administered intravenously to laboratory animals and humans. Lymphokine activated killer (LAK) cells are white blood cells that have been stimulated with IL-2 in vitro. LAK cells are capable of killing tumor cells both in vitro and in vivo, especially when given along with IL-2. Although this form of treatment has been found to be effective in patients with certain cancers who no longer benefit from standard forms of therapy, the anti-cancer effects of IL-2/LAK cell treatment are limited by the serious, life-threatening side effects of high-dose intravenous administration, and by the high cost. A treatment program with low-dose, intralymphatically-administered LAK/IL-2 in patients with advanced cancer is a promising alternative which circumvents these major problems and concerns, while maintaining high response rates. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
